Literature DB >> 34799483

RASGRF1-rearranged Cutaneous Melanocytic Neoplasms With Spitzoid Cytomorphology: A Clinicopathologic and Genetic Study of 3 Cases.

Keisuke Goto1,2,3,4,5,6,7, Daniel Pissaloux8,9, Sylvie Fraitag10,11, Mona Amini12, Richard Vaucher13, Franck Tirode8,9, Arnaud de la Fouchardière8,9.   

Abstract

Spitz neoplasms, according to 2018 WHO Blue Book, are morphologically defined by spindled and/or epithelioid melanocytes and genetically by either HRAS mutations or kinase gene fusions. The terminology "spitzoid" refers to lesions with similar morphology but with alternate or undefined genetic anomalies. Herein, we present 3 melanocytic neoplasms with a spitzoid cytomorphology, variable nuclear atypia, and harboring undescribed fusions involving RASGRF1. Two cases presented as unpigmented papules on the heel of a 26-year-old female (case 1) and the forearm of a 13-year-old boy (case 2). They were classified as low-grade melanocytomas (WHO 2018). The third case appeared as a pigmented ulcer on the sole of a 72-year-old female (case 3) that displayed diagnostic features of an invasive melanoma (Breslow thickness 6 mm, Clark level V). A wide skin reexcision identified an epidermotropic metastasis, and sentinel lymph node biopsy displayed multiple subcapsular metastatic deposits. RNA sequencing revealed CD63::RASGRF1, EHBP1::RASGRF1, and ABCC2::RASGRF1 fusions in cases 1 to 3, respectively. They were confirmed by a RASGRF1 break-apart fluorescence in situ hybridization technique. Translocations of RASGRF1, a gene coding a guanine nucleotide exchange factor but not a kinase, have rarely been reported in tumors. While all these cases showed spitzoid cytomorphology, it is too early to tell if they are true Spitz neoplasms as currently defined.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34799483     DOI: 10.1097/PAS.0000000000001839

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

1.  RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.

Authors:  Lisa Hunihan; Dejian Zhao; Heather Lazowski; Man Li; Yuping Qian; Laura Abriola; Yulia V Surovtseva; Viswanathan Muthusamy; Lynn T Tanoue; Bonnie E Gould Rothberg; Kurt A Schalper; Roy S Herbst; Frederick H Wilson
Journal:  Clin Cancer Res       Date:  2022-07-15       Impact factor: 13.801

2.  All About That Ras: Novel Fusion Drives Ras Pathway Activation in Lung Cancer.

Authors:  Sitapriya Moorthi; Alice H Berger
Journal:  Clin Cancer Res       Date:  2022-07-15       Impact factor: 13.801

Review 3.  The Spectrum of Spitz Melanocytic Lesions: From Morphologic Diagnosis to Molecular Classification.

Authors:  Tiffany W Cheng; Madeline C Ahern; Alessio Giubellino
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.